OBJECTIVE: To investigate whether preoperative hepatic and regional arterial chemotherapy is able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer resection. METHODS:Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112). The primary endpoint was disease-free survival, whereas the secondary endpoints included liver metastasis-free survival and overall survival. RESULTS: There were no significant differences in overall morbidity between PHRAC and Control groups. During the follow-up period (median, 36 months), the median liver metastasis time for patients with stageIII CRC was significantly longer in the PHRAC group (16 +/- 3 months vs. 8 +/- 1 months, P = 0.01). In stage III patients, there was also significant difference between the 2 groups with regard to the incidence of liver metastasis (20.6% vs. 28.3%, P = 0.03), 3-year disease-free survival (74.6% vs. 58.1%, P = 0.0096), 3-year overall survival (87.7% vs. 75.7%, P = 0.020), and the median survival time (40.1 +/- 4.6 months vs. 36.3 +/- 3.2 months, P = 0.03). In the PHRAC arm, the risk ratio of recurrence was 0.61 (95% CI, 0.51-0.79, P = 0.0002), of death was 0.51 (95% CI, 0.32-0.67; P = 0.009), and of liver metastasis was 0.73 (95% CI, 0.52-0.86; P = 0.02). In contrast, PHRAC seemed to be no benefit for stage II patients. Toxicities, such as hepatic toxicity and leukocyte decreasing, were mild and could be cured with medicine. CONCLUSIONS:Preoperative hepatic and regional arterial chemotherapy, in combination with surgical resection, could be able to reduce and delay the occurrence of liver metastasis and therefore improve survival rate in patients with stage III colorectal cancer.
RCT Entities:
OBJECTIVE: To investigate whether preoperative hepatic and regional arterial chemotherapy is able to prevent liver metastasis and improve overall survival in patients receiving curative colorectal cancer resection. METHODS:Patients with stage II or stage III colorectal cancer (CRC) were randomly assigned to receive preoperative hepatic and regional arterial chemotherapy (PHRAC group, n = 110) or surgery alone (control group, n = 112). The primary endpoint was disease-free survival, whereas the secondary endpoints included liver metastasis-free survival and overall survival. RESULTS: There were no significant differences in overall morbidity between PHRAC and Control groups. During the follow-up period (median, 36 months), the median liver metastasis time for patients with stage III CRC was significantly longer in the PHRAC group (16 +/- 3 months vs. 8 +/- 1 months, P = 0.01). In stage III patients, there was also significant difference between the 2 groups with regard to the incidence of liver metastasis (20.6% vs. 28.3%, P = 0.03), 3-year disease-free survival (74.6% vs. 58.1%, P = 0.0096), 3-year overall survival (87.7% vs. 75.7%, P = 0.020), and the median survival time (40.1 +/- 4.6 months vs. 36.3 +/- 3.2 months, P = 0.03). In the PHRAC arm, the risk ratio of recurrence was 0.61 (95% CI, 0.51-0.79, P = 0.0002), of death was 0.51 (95% CI, 0.32-0.67; P = 0.009), and of liver metastasis was 0.73 (95% CI, 0.52-0.86; P = 0.02). In contrast, PHRAC seemed to be no benefit for stage II patients. Toxicities, such as hepatic toxicity and leukocyte decreasing, were mild and could be cured with medicine. CONCLUSIONS: Preoperative hepatic and regional arterial chemotherapy, in combination with surgical resection, could be able to reduce and delay the occurrence of liver metastasis and therefore improve survival rate in patients with stage III colorectal cancer.
Authors: N Kemeny; Y Huang; A M Cohen; W Shi; J A Conti; M F Brennan; J R Bertino; A D Turnbull; D Sullivan; J Stockman; L H Blumgart; Y Fong Journal: N Engl J Med Date: 1999-12-30 Impact factor: 91.245
Authors: L Weiss; E Grundmann; J Torhorst; F Hartveit; I Moberg; M Eder; C M Fenoglio-Preiser; J Napier; C H Horne; M J Lopez Journal: J Pathol Date: 1986-11 Impact factor: 7.996
Authors: N Wolmark; H Rockette; D L Wickerham; B Fisher; C Redmond; E R Fisher; M Potvin; R J Davies; J Jones; A Robidoux Journal: J Clin Oncol Date: 1990-09 Impact factor: 44.544
Authors: Mark Bonnen; Christopher Crane; Jean-Nicolas Vauthey; John Skibber; Marc E Delclos; Miguel Rodriguez-Bigas; Paulo M Hoff; Edward Lin; Cathy Eng; Adrian Wong; Nora A Janjan; Barry W Feig Journal: Int J Radiat Oncol Biol Phys Date: 2004-11-15 Impact factor: 7.038
Authors: P Piedbois; M Buyse; N Kemeny; P Rougier; R Carlson; T Allen-Mersh; M O'Connell; A Chang; V Sondak; M Kemeny; E Levy Journal: J Natl Cancer Inst Date: 1996-03-06 Impact factor: 13.506
Authors: John M Creasy; Kristen M Cunanan; Jayasree Chakraborty; John C McAuliffe; Joanne Chou; Mithat Gonen; Victoria S Kingham; Martin R Weiser; Vinod P Balachandran; Jeffrey A Drebin; T Peter Kingham; William R Jarnagin; Michael I D'Angelica; Richard K G Do; Amber L Simpson Journal: Ann Surg Oncol Date: 2020-09-20 Impact factor: 5.344
Authors: Christian Heiliger; Jerzy Piecuch; Alexander Frank; Dorian Andrade; Viktor von Ehrlich-Treuenstätt; Dobromira Evtimova; Florian Kühn; Jens Werner; Konrad Karcz Journal: Sci Rep Date: 2021-07-20 Impact factor: 4.379